BIVIW

BioVie Inc. Warrants represent the right to purchase shares of BioVie common stock at a predetermined exercise price during a specified time period. These warrants were issued as part of previous financing transactions and provide holders with leveraged exposure to BioVie's prospects in developing therapies for liver diseases and neurological disorders. The warrants trade separately from the common stock and appeal to investors seeking amplified participation in potential appreciation as the company advances its clinical programs, particularly BIV201 for liver cirrhosis and NE3107 for Alzheimer's disease. As derivative securities, these warrants' value derives from the underlying BioVie common stock price. When the stock price rises above the warrant's exercise price, the warrants gain intrinsic value. Additionally, warrants possess time value based on the remaining exercise period and expected stock volatility. This leverage characteristic enables warrants to deliver larger percentage returns than the underlying stock during appreciation periods, though they also carry higher risk, potentially declining more sharply during downturns and expiring worthless if the stock price remains below the exercise price at expiration. BioVie is advancing BIV201 (continuous infusion terlipressin) for ascites in liver cirrhosis patients and NE3107 for Alzheimer's disease, addressing conditions with large patient populations and significant unmet needs. The company's ability to successfully complete clinical trials, demonstrate efficacy and safety, achieve regulatory approvals, secure strategic partnerships, or reach other positive milestones could drive stock price appreciation, creating value for warrant holders. These instruments suit investors with higher risk tolerance who believe in BioVie's clinical programs and the potential for successful development and commercialization of therapies for serious liver and neurological diseases. The warrant investment thesis depends on clinical trial success, regulatory approval pathways, and eventual commercial viability of the company's drug candidates.